drugset / Trial / NCT00152295

A Long-Term Study to Evaluate the Safety of Asoprisnil and Estrogen Administration to Postmenopausal Women

NCT00152295

Phase 2 Completed 18 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to determine the long-term safety of asoprisnil 10 mg when administered to postmenopausal women with Premarin® 0.625 mg

Timeline

Start
2001-04
Primary completion
2001-12
Completion
2001-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Asoprisnil Other / unclassified 10 mg Oral
Background conjugated estrogens Other / unclassified 0.625 mg Oral

Indications

No indication recorded.